BioAtla to cut 70% of staff and pursue asset sales

BioAtla said it will slash roughly 70% of its workforce and has launched a formal strategic review as mounting cash constraints force the San Diego clinical-stage biotech to consider monetizing assets. In a press release the company said its Board “has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including the sale of preclinical and clinical assets, licensing transactions, strategic partnerships or other corporate transactions.”

Company executives described the move as part of broader cost containment. “The Company is implementing a restructuring plan to significantly reduce operating expenses, including a workforce reduction of approximately 70% and expansion of our cost-containment measures,” the statement said. Management added that it “intends to retain all employees essential for supporting value creation as part of its strategic review.”

The cut follows a prior reduction in 2025 that trimmed about 30% of staff as the firm aimed to extend its runway into the first half of 2026. BioAtla reported roughly $7.1 million in cash and cash equivalents as of December 31, 2025, down from about $8.3 million at the end of September. The company said it received and repaid $7.5 million under pre-paid advance agreements and retains the option, subject to conditions, to sell up to $15.0 million of common stock under a standby equity purchase agreement.

Leadership changes accompanied the restructuring. The company terminated Chief Financial Officer Richard Waldron effective March 2, with terms described as “with severance and accelerated equity vesting.” Chris Vasquez, previously chief accounting officer, was promoted to chief financial officer and principal financial officer, “with no change in compensation.” The company also amended a previously announced merger agreement to preserve its existing certificate of incorporation and governance provisions, and it has engaged an adviser to steer the strategic review.

A looming $40.0 million transaction is a central financial unknown. Company statements and filings signal a year-end $40.0 million arrangement tied to advancing an asset into a Phase 3 program; the company is now renegotiating that planned transaction. The outcome of that negotiation will be pivotal to BioAtla’s cash runway and any decision to sell or license assets such as the Oz-V candidate tied to the deal.

For investors and markets, the package presents three clear risks: sharp near-term reductions in R&D capacity, potential dilution if equity is sold under the standby agreement, and uncertainty over realization of the $40.0 million financing. The company estimates severance and related benefit payments for the layoffs will total roughly $0.5 million to $0.6 million, mostly paid in the first quarter of 2026, a modest near-term cash outlay relative to the scale of the workforce reduction.

The move underscores a broader trend in biotech where smaller drug developers pivot from internal development to asset-light models, licensing and partnership strategies as public and private capital costs rise. Companies with late-stage assets or strong patent positions can attract deals or special purpose vehicle financings, but those agreements are often fragile when sponsors face their own funding limits.

BioAtla’s CAB antibody platform, its Phase 2 and Phase 3 ADC and T-cell engager programs, and a portfolio of more than 500 issued patents give it potential levers to monetize value. The strategic review will determine whether the firm pursues asset sales, licensing, partnerships, or other corporate transactions. Investors will be watching upcoming SEC filings for detailed terms and any definitive agreements that follow the review.